CA2386398A1 - Peptides et peptidomimetiques modifies destines a l'immunotherapie - Google Patents

Peptides et peptidomimetiques modifies destines a l'immunotherapie Download PDF

Info

Publication number
CA2386398A1
CA2386398A1 CA002386398A CA2386398A CA2386398A1 CA 2386398 A1 CA2386398 A1 CA 2386398A1 CA 002386398 A CA002386398 A CA 002386398A CA 2386398 A CA2386398 A CA 2386398A CA 2386398 A1 CA2386398 A1 CA 2386398A1
Authority
CA
Canada
Prior art keywords
ser
gly
thr
ala
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002386398A
Other languages
English (en)
Inventor
Catherina Joanna Van Staveren
Cornelis Marius Timmers
Philippus Johannes Marie Galen Van
Rnaldus Marcellus Alphonsus Knegtel
Anna Maria Helena Boots
Andreas Martinus Maria Miltenburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2386398A1 publication Critical patent/CA2386398A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un peptide modifié dérivé de H-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH correspondant à la formule générale (II) Q-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-Z. Dans la formule générale (II), les symboles A1 à A13 correspondent aux aminoacides de la formule (I), Q correspond à H et Z correspond à OH. Les modifications selon la présente invention sont réalisées, de façon sélective, dans au moins un des groupes a, b ou c, et sont les suivantes a) substitution de 1-6, de préférence 1-4 aminoacides au niveau de A1 à A13 par des aminoacides non naturels ou des aminoacides .beta.; b) substitution d'une ou de plusieurs liaisons amide par des liaisons amide réduites ou des isostères éthylène; c) substitutions au niveau de Q et/ou Z ; et éventuellement, d) substitution d'aminoacides naturels. Le nombre total de ces modifications est de 6. Ces peptides servent à induire une tolérance chez les patients souffrant de maladies auto-immunes.
CA002386398A 1999-10-18 2000-10-12 Peptides et peptidomimetiques modifies destines a l'immunotherapie Abandoned CA2386398A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99203427 1999-10-18
EP99203427.2 1999-10-18
PCT/EP2000/010230 WO2001029081A1 (fr) 1999-10-18 2000-10-12 Peptides et peptidomimetiques modifies destines a l'immunotherapie

Publications (1)

Publication Number Publication Date
CA2386398A1 true CA2386398A1 (fr) 2001-04-26

Family

ID=8240756

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002386398A Abandoned CA2386398A1 (fr) 1999-10-18 2000-10-12 Peptides et peptidomimetiques modifies destines a l'immunotherapie

Country Status (23)

Country Link
EP (1) EP1226167A1 (fr)
JP (1) JP2003512388A (fr)
KR (1) KR20020047245A (fr)
CN (1) CN1379786A (fr)
AR (1) AR026068A1 (fr)
AU (1) AU780238B2 (fr)
BR (1) BR0014803A (fr)
CA (1) CA2386398A1 (fr)
CO (1) CO5271650A1 (fr)
CZ (1) CZ20021356A3 (fr)
HK (1) HK1046693A1 (fr)
HU (1) HUP0203504A3 (fr)
IL (1) IL148778A0 (fr)
MX (1) MXPA02003520A (fr)
NO (1) NO20021763L (fr)
NZ (1) NZ518256A (fr)
PE (1) PE20010692A1 (fr)
PL (1) PL354590A1 (fr)
RU (1) RU2002113107A (fr)
SK (1) SK6842002A3 (fr)
TR (1) TR200201036T2 (fr)
WO (1) WO2001029081A1 (fr)
ZA (1) ZA200202577B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951212A0 (en) * 2002-09-04 2002-09-19 Monash University A method of modulating cellular activity and molecules for use therein
AU2007235305A1 (en) * 2006-04-06 2007-10-18 Purdue Research Foundation Derivatization-enhanced analysis of amino acids and peptides
EP2114462B1 (fr) * 2006-12-21 2013-06-05 Universite De Geneve Composés destinés à des applications d'imagerie par fluorescence
WO2009092381A1 (fr) 2008-01-23 2009-07-30 Herlev Hospital, Region Hovedstaden Ykl-40 en tant que marqueur général pour une maladie non spécifique
WO2010028658A1 (fr) 2008-09-15 2010-03-18 Herlev Hospital, Region Hovedstaden Ykl-40 en tant que marqueur pour les cancers gastro-intestinaux
TWI777260B (zh) 2014-11-07 2022-09-11 美商奇尼塔慢性疼痛有限責任公司 芋螺毒素(conotoxin)肽之修飾及用途
EP3466963A1 (fr) * 2017-10-05 2019-04-10 Suigeneris Farmacosmetics, S.L. Peptides anticancer et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115744A (en) * 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
IL120561A0 (en) * 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
CN1130372C (zh) * 1996-06-07 2003-12-10 曾尼卡有限公司 肽衍生物
IL122233A (en) * 1996-12-06 2001-04-30 Akzo Nobel Nv Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them

Also Published As

Publication number Publication date
HUP0203504A3 (en) 2005-03-29
ZA200202577B (en) 2003-09-23
NZ518256A (en) 2004-01-30
PL354590A1 (en) 2004-01-26
CZ20021356A3 (cs) 2002-07-17
EP1226167A1 (fr) 2002-07-31
PE20010692A1 (es) 2001-07-06
HUP0203504A2 (hu) 2003-04-28
NO20021763D0 (no) 2002-04-15
BR0014803A (pt) 2002-06-11
HK1046693A1 (zh) 2003-01-24
WO2001029081A1 (fr) 2001-04-26
AU1139601A (en) 2001-04-30
IL148778A0 (en) 2002-09-12
JP2003512388A (ja) 2003-04-02
AR026068A1 (es) 2002-12-26
NO20021763L (no) 2002-04-15
RU2002113107A (ru) 2004-01-10
CO5271650A1 (es) 2003-04-30
TR200201036T2 (tr) 2002-08-21
KR20020047245A (ko) 2002-06-21
AU780238B2 (en) 2005-03-10
CN1379786A (zh) 2002-11-13
MXPA02003520A (es) 2002-08-20
SK6842002A3 (en) 2002-09-10

Similar Documents

Publication Publication Date Title
Demotz et al. Delineation of several DR-restricted tetanus toxin T cell epitopes.
US6509033B1 (en) Immunomodulatory peptides
US20070031445A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
KR20070026450A (ko) 자가면역 질환과 관련된 자가 항원 및 비자가 항원의 동정방법
WO1998005684A9 (fr) Oligomeres peptidiques de liaison cmh et procedes d'utilisation
JPH09507861A (ja) 自己免疫疾患の免疫療法に用いるための、自己抗原から誘導された新規なペプチド
US7122193B1 (en) Retro peptides, antibodies thereto and their uses for vaccination and in vitro diagnosis
AU780238B2 (en) Modified peptides and peptidomimetics for use in immunotherapy
HRP970099A2 (en) Peptide derivatives
Maillère et al. Fine chemical modifications at N-and C-termini enhance peptide presentation to T cells, by increasing the lifespan of both free and MHC-complexed peptides
CA2223714A1 (fr) Vaccination par peptides de molecules du cmh de classe ii destinee au traitement de maladie auto-immune
Sakarellos-Daitsiotis et al. Artificial carriers: a strategy for constructing antigenic/immunogenic conjugates
AU2002339227A1 (en) Triple polypeptide complexes
WO2003006603A2 (fr) Complexes triple de polypeptides
WO1998013378A1 (fr) Peptides mannosyles
US20040141995A1 (en) MHC class I-restricted and MHC class II-restricted EBNA1 peptides
AU758310B2 (en) Novel peptides for use in immunotherapy of autoimmune diseases
US6423315B1 (en) Synthetic peptide for treatment of autoimmune arthritis
Skarlas et al. HLA‐DQ7 β1 and β2 derived peptides as immunomodulators
Paz Antigenic peptides presented by MHC-I undergo intermediate processing steps in the cytosol and the endoplasmic reticulum
AU4863900A (en) Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease

Legal Events

Date Code Title Description
FZDE Discontinued